Tumor Biology

, Volume 34, Issue 5, pp 3121–3130 | Cite as

P53 codon 72 Arg/Pro polymorphism and glioma risk: an updated meta-analysis

  • Fang He
  • Yi Xia
  • Huafeng Liu
  • Jin Li
  • Chao Wang
Research Article


P53 codon 72 Arg/Pro is a C/G variation upstream of the p53 gene on human chromosome 17p13. Many case–control studies have investigated the association between p53 codon 72 Arg/Pro polymorphism and glioma risk but provided inconsistent findings. To better understand the pathogenesis of glioma, we performed the current meta-analysis by pooling data from all available individual studies. According to the inclusion criteria, ten independent publications with 11 case–control studies were included into this meta-analysis. The pooled odds ratio (OR) with 95 % confidence interval (95 % CI) was calculated to estimate the effect of p53 codon 72 Arg/Pro variant on the development of glioma. Overall, no appreciable correlation was observed among the total studies in all gene models (ORPro allele vs. Arg allele = 1.04, 95 % CI = 0.90–1.20, P OR = 0.581; ORPro/Pro vs. Arg/Arg = 0.95, 95 % CI = 0.80–1.14, P OR = 0.614; ORPro/Arg vs. Arg/Arg = 1.01, 95 % CI = 0.79–1.29, P OR = 0.993; ORPro/Arg + Pro/Pro vs. Arg/Arg = 1.03, 95 % CI = 0.82–1.29, P OR = 0.799; ORPro/Pro vs. Arg/Arg + Pro/Arg = 1.02, 95 % CI = 0.86–1.22, P OR = 0.785). In stratified analyses by ethnicity, source of controls, and glioma subtypes, the p53 codon 72 Arg/Pro polymorphism did not alter the risk for glioma in population-based, hospital-based, astrocytoma, and oligodendroglioma studies among Caucasian. Interestingly, the Pro/Pro genotype seemed to be negatively associated with the glioma risk among patients with glioblastoma (ORPro/Pro vs. Arg/Arg = 0.68, 95 % CI = 0.48–0.95, P OR = 0.026). Our study suggests that the polymorphism of p53 codon 72 Arg/Pro may play a protective role in the development of glioblastoma. The relationship of p53 codon 72 Arg/Pro polymorphism with the susceptibility to glioma needs further estimation by more individual studies with high quality across ethnicities.


P53 Glioma Polymorphism Meta-analysis 


Conflicts of interest



  1. 1.
    Rickert CH, Paulus W. Epidemiology of central nervous system tumors in childhood and adolescence based on the new WHO classification. Childs Nerv Syst. 2001;17:503–11.CrossRefPubMedGoogle Scholar
  2. 2.
    Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genet. 2012;205:613–21.CrossRefPubMedGoogle Scholar
  3. 3.
    Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.CrossRefPubMedGoogle Scholar
  4. 4.
    Ohgaki H. Epidemiology of brain tumors. Methods Mol Biol. 2009;472:323–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Backes DM, Siddiq A, Cox DG, Calboli FC, Gaziano JM, Ma J, et al. Single-nucleotide polymorphisms of allergy-related genes and risk of adult glioma. J Neurooncol. 2013.Google Scholar
  6. 6.
    Wang D, Hu Y, Gong H, Li J, Ren Y, Li G, et al. Genetic polymorphisms in the DNA repair gene XRCC1 and susceptibility to glioma in a Han population in northeastern China: a case–control study. Gene. 2012;509:223–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Hou WG, Ai WB, Bai XG, Dong HL, Li Z, Zhang YQ, et al. Genetic variation in the EGFR gene and the risk of glioma in a Chinese Han population. PLoS One. 2012;7:e37531.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Fan Y, Lee TV, Xu D, Chen Z, Lamblin AF, Steller H, et al. Dual roles of Drosophila p53 in cell death and cell differentiation. Cell Death Differ. 2010;17:912–21.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Alsafadi S, Tourpin S, Andre F, Vassal G, Ahomadegbe JC. P53 family: at the crossroads in cancer therapy. Curr Med Chem. 2009;16:4328–44.CrossRefPubMedGoogle Scholar
  10. 10.
    Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Suzuki K, Matsubara H. Recent advances in p53 research and cancer treatment. J Biomed Biotechnol. 2011;2011:978312.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Kim SH, Dass CR. p53-targeted cancer pharmacotherapy: move towards small molecule compounds. J Pharm Pharmacol. 2011;63:603–10.CrossRefPubMedGoogle Scholar
  13. 13.
    Olsson H, Hultman P, Rosell J, Soderkvist P, Jahnson S. MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1. BMC Urol. 2013;13:5.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Singhal P, Hussain S, Thakur N, Batra S, Salhan S, Bhambani S, et al. Association of MDM2 and p53 polymorphisms with the advancement of cervical carcinoma. DNA Cell Biol. 2013;32:19–27.CrossRefPubMedGoogle Scholar
  15. 15.
    Habbous S, Pang V, Eng L, Xu W, Kurtz G, Liu FF, et al. p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res. 2012;18:6407–15.CrossRefPubMedGoogle Scholar
  16. 16.
    Sakurai N, Iwamoto S, Miura Y, Nakamura T, Matsumine A, Nishioka J, et al. Novel p53 splicing site mutation in Li-Fraumeni-like syndrome with osteosarcoma. Pediatr Int. 2013;55:107–11.CrossRefPubMedGoogle Scholar
  17. 17.
    Wang LE, Bondy ML, Shen H, El-Zein R, Aldape K, Cao Y, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 2004;64:5560–3.CrossRefPubMedGoogle Scholar
  18. 18.
    Parhar P, Ezer R, Shao Y, Allen JC, Miller DC, Newcomb EW. Possible association of p53 codon 72 polymorphism with susceptibility to adult and pediatric high-grade astrocytomas. Brain Res Mol Brain Res. 2005;137:98–103.CrossRefPubMedGoogle Scholar
  19. 19.
    Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Criniere E, et al. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet. 2007;177:103–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Malmer BS, Feychting M, Lonn S, Lindstrom S, Gronberg H, Ahlbom A, et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 2007;82:229–37.CrossRefPubMedGoogle Scholar
  21. 21.
    Rajaraman P, Wang SS, Rothman N, Brown MM, Black PM, Fine HA, et al. Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev. 2007;16:1655–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, Silva A, Amorim J, et al. TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet. 2008;180:14–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Pinto GR, Yoshioka FK, Silva RL, Clara CA, Santos MJ, Almeida JR, et al. Prognostic value of TP53 Pro47Ser and Arg72Pro single nucleotide polymorphisms and the susceptibility to gliomas in individuals from Southeast Brazil. Genet Mol Res. 2008;7:207–16.CrossRefPubMedGoogle Scholar
  24. 24.
    El Hallani S, Ducray F, Idbaih A, Marie Y, Boisselier B, Colin C, et al. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology. 2009;72:332–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Jha P, Pathak P, Chosdol K, Suri V, Sharma MC, Kumar G, et al. TP53 polymorphisms in gliomas from Indian patients: study of codon 72 genotype, rs1642785, rs1800370 and 16 base pair insertion in intron-3. Exp Mol Pathol. 2011;90:167–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Jin T, Zhang J, Li G, Li S, Yang B, Chen C, et al. TP53 and RPA3 gene variations were associated with risk of glioma in a Chinese Han population. Cancer Biother Radiopharm. 2013;28:248–53.CrossRefPubMedGoogle Scholar
  27. 27.
    Cochran WG. The comparison of percentages in matched samples. Biometrika. 1950;37:256–66.CrossRefPubMedGoogle Scholar
  28. 28.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCentralCrossRefPubMedGoogle Scholar
  29. 29.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  30. 30.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  31. 31.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Stuck AE, Rubenstein LZ, Wieland D. Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity. BMJ. 1998;316:469. author reply 70-1.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Giannini C, Hebrink D, Scheithauer BW, Dei Tos AP, James CD. Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. Neurogenetics. 2001;3:159–62.CrossRefPubMedGoogle Scholar
  34. 34.
    Hayes VM, Dirven CM, Dam A, Verlind E, Molenaar WM, Mooij JJ, et al. High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors. Brain Pathol. 1999;9:463–7.CrossRefPubMedGoogle Scholar
  35. 35.
    Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Criniere E, et al. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. 2008;1198:16–20.CrossRefPubMedGoogle Scholar
  36. 36.
    Patt S, Gries H, Giraldo M, Cervos-Navarro J, Martin H, Janisch W, et al. p53 gene mutations in human astrocytic brain tumors including pilocytic astrocytomas. Hum Pathol. 1996;27:586–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Zawlik I, Kita D, Vaccarella S, Mittelbronn M, Franceschi S, Ohgaki H. Common polymorphisms in the MDM2 and TP53 genes and the relationship between TP53 mutations and patient outcomes in glioblastomas. Brain Pathol. 2009;19:188–94.CrossRefPubMedGoogle Scholar
  38. 38.
    Zhu HB, Yang K, Xie YQ, Lin YW, Mao QQ, Xie LP. Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol. 2013;11:22.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. J Urol. 2003;169:1219–28.CrossRefPubMedGoogle Scholar
  40. 40.
    Buyru N, Tigli H, Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep. 2003;10:711–4.PubMedGoogle Scholar
  41. 41.
    Kara N, Karakus N, Ulusoy AN, Ozaslan C, Gungor B, Bagci H. P53 codon 72 and HER2 codon 655 polymorphisms in Turkish breast cancer patients. DNA Cell Biol. 2010;29:387–92.CrossRefPubMedGoogle Scholar
  42. 42.
    Shi M, Huang R, Pei C, Jia X, Jiang C, Ren H. TP53 codon 72 polymorphism and glioma risk: a meta-analysis. Oncol Lett. 2012;3:599–606.PubMedCentralPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Fang He
    • 1
  • Yi Xia
    • 2
  • Huafeng Liu
    • 2
  • Jin Li
    • 3
  • Chao Wang
    • 2
  1. 1.Tangdu HospitalFourth Military Medical UniversityXi’anChina
  2. 2.Department of Neurosurgery, Tangdu HospitalFourth Military Medical UniversityXi’anChina
  3. 3.Beijing Liberation Army 316 HospitalBeijingChina

Personalised recommendations